Navigation Links
TGen Drug Development recognized for economic development of Arizona biosciences
Date:9/28/2011

SCOTTSDALE, Ariz. Sept. 28, 2011 TGen Drug Development (TD2) won a Fast Lane award from the Arizona BioIndustry Association (AZBio) for promoting the economic development of Arizona biosciences.

TD2, a subsidiary of the Translational Genomics Research Institute (TGen), provides world-class clinical and regulatory expertise to biopharmaceutical companies using cutting-edge technology to minimize the risks in cancer drug development. TD2 works to shorten the development cycles for anti-cancer agents and improve their success rates.

"TD2 is at the forefront of helping pharmaceutical companies navigate the regulatory system to get the safest, most effective compounds as quickly as possible to the patients who need them," said Dr. Stephen Gately, President and Chief Scientific Officer of TD2. "This award not only recognizes the good work of TD2, but is reflective of all the advancements of TGen, and of our collaborators."

Another recipient of a Fast Lane award is Flagship Biosciences, which provides tissue analysis services. Earlier this year, the Flagstaff company forged a strategic alliance with TD2 to help speed new drugs safely into human testing, where they can quickly benefit cancer patients.

Since 2002, according to Battelle: jobs in Arizona's bioscience industry grew 32 percent; the number of bioscience and related firms including research, manufacturing, testing, medical labs, and healthcare delivery systems grew 28 percent; and research partnerships with the National Institutes of Heath (NIH) increased 65 percent. Arizona bioscience organizations now generate $21 billion in annual revenues and $765 million in state and local taxes.

"These are measurable results from a community committed to working together to build a world-class research base, support commercialization efforts, and migrate the latest discoveries from the bench to the bedside in a manner that is both translational and transformational, " s
'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Page: 1 2

Related biology news :

1. Fast-evolving genes control developmental differences in social insects
2. Report showcases success of integrated development approaches
3. New roles emerge for non-coding RNAs in directing embryonic development
4. Recipients of the 2011 Postdoctoral Professional Development and Enrichment Award
5. Cells derived from pluripotent stem cells are developmentally immature
6. Genomewide mapping reveals developmental and environmental impacts
7. Childhood eye tumor made up of hybrid cells with jumbled development
8. Toronto researchers first to discover new genetic clue in the development of rheumatoid arthritis
9. FASEB MARC program announces the travel award recipients for the 2011 Leadership Development and Grant Writing Seminar for graduate students, postdoctoral fellows and new assistant professors
10. Genetic analysis of amniotic fluid shows promise for monitoring fetal development
11. Novel analysis by Allen Institute sheds new light on the mechanisms of brain development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of ... report to their offering. One ... adoption of multimodal biometric systems. Multimodal biometric systems ... for verification and identification purposes. This helps to ...
(Date:12/10/2014)... -- Valencell, a leader in performance biometric data sensor technology, ... its licensees for highly accurate, clinically validated biometric technology. ... from fitness and health sectors, but first responders/military and ... only as useful as the biometric data it delivers. ... long-term mass consumer adoption of wearable products," said Dr. ...
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... 2011 Reportlinker.com announces that a new market ... Biobanking: Technologies and Global Markets ... REPORT HIGHLIGHTS THIS REPORT ... biobanks by types: Population, Disease, and Private Sector ...
... YORK, July 14, 2011 ,   ... for consumer wellness applications,today announced that it has entered into ... US$5 Million equity,line facility. Under the terms of ... has the option to sell and Dutchess the,obligation to purchase ...
... Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its second quarter ended June 30, 2011.   Revenue ... of 19% compared to $5.0 million in the same quarter last ... $267,000, or $0.01 per diluted share. These results compared to a ...
Cached Biology News:Biobanking: Technologies and Global Markets 2Biobanking: Technologies and Global Markets 3Biobanking: Technologies and Global Markets 4Biobanking: Technologies and Global Markets 5Biobanking: Technologies and Global Markets 6Biobanking: Technologies and Global Markets 7Biobanking: Technologies and Global Markets 8Biobanking: Technologies and Global Markets 9Biobanking: Technologies and Global Markets 10Biobanking: Technologies and Global Markets 11Biobanking: Technologies and Global Markets 12Biobanking: Technologies and Global Markets 13SPO Secures Equity Line Facility of US$5 Million 2SPO Secures Equity Line Facility of US$5 Million 3SPO Secures Equity Line Facility of US$5 Million 4Aware, Inc. Reports Second Quarter 2011 Financial Results 2Aware, Inc. Reports Second Quarter 2011 Financial Results 3Aware, Inc. Reports Second Quarter 2011 Financial Results 4Aware, Inc. Reports Second Quarter 2011 Financial Results 5
(Date:12/24/2014)... ST. LOUIS , Dec. 23, 2014 /PRNewswire/ ... announced today that the waiting period under the ... with the acquisition expired on December 22, 2014, ... and review requirement for the acquisition of the ... U.S. antitrust clearance satisfies another condition to ...
(Date:12/22/2014)... Dec. 22, 2014   Synthetic Biologics, ... of pathogen-specific therapies for serious infections and ... microbiome, today announced positive topline safety and ... trial of SYN-004, the Company,s investigational oral ... Clostridium difficile (C. difficile) infection, antibiotic-associated ...
(Date:12/22/2014)... , Dec. 22, 2014  ( www.competitivehealth.com ) — ... online medical bill review and advocacy service, has signed ... FREE WellCard Savings discount health services marketplace. ... was more than they expected to pay. As part ... care costs, WellCard Savings is pleased to offer medical ...
(Date:12/19/2014)... and Hershey, PA (PRWEB) December 19, 2014 ... BJCT), a leading developer and manufacturer of needle-free ... into an agreement with Immunomic Therapeutics, Inc. (“ITI”) ... needle-free injection device with its LAMP™ vaccine platform. ... option for an exclusive Worldwide license to the ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... Australia, Jan. 30 Phosphagenics,Limited ("Phosphagenics") (ASX: POH, ... pre-clinical study demonstrating that the,combination of its APA- ... reduced serum lipids and inflammatory proteins,involved in the ... purpose of the study was to determine whether ...
... 30 Sagent Pharmaceuticals, Inc.,a privately-held specialty pharmaceutical ... that Ronald E. Pauli, chief financial,officer, will present ... Device Conference on Tuesday, February 5, 2008,at 11 ... 5-7, 2008 at the Grand,Hyatt Hotel in New ...
... Medical,Inc. (TASE: TOPMD) announces first commercial installation of ... Belgium,with the first procedures performed on January 16th., ... site to install the Cathamaran(TM),IVMRI System. This 6F ... to detect and quantify lipid present in coronary ...
Cached Biology Technology:Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination 2Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination 3Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination 4Topspin Medical Announces First Commercial Installation of the Cathamaran(TM) Intravascular MRI System 2Topspin Medical Announces First Commercial Installation of the Cathamaran(TM) Intravascular MRI System 3
... Detection of the yolk protein Vtg in plasma ... and sensitive biomarker for endocrine disrupting chemicals (EDCs) ... has become an accepted screening test for the ... (rainbow trout) EIA kit is a double-antibody immunometric ...
... whose sequence is from rat SCAMP 5. The sequence of ... - Q - P - Q - T - Q - ... - Y - T - Y - S - N(233). ... with the polyclonal antibody that reacts with this product and the ...
... which no antibody exists? Having difficulty generating antibodies ... variety of pharmaceutical, biotech and academic researchers and ... and expertise in antibody generation to work for ... development technology , High affinity and high specificity ...
... Panels were designed for full-length gene cloning ... to identify the desired cDNA clone. The ... 96-well "Master Plate," where each well contains ... the positive well(s) by gel electrophoresis of ...
Biology Products: